Page 1

November 15 , 2021 KIORA PHARMACEUTICALS Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update SALT LAKE CITY , Nov. 15 , 2021 ( GLOBE NEWSWIRE ) -- Kiora Pharmaceuticals , Inc. ( NASDAQ : KPRX ) , ( " Kiora ” or the “ Company ” ) today reported its financial results for the quarter ended September 30 , 2021 and provided an update on recent corporate and operational activities . " We recently sharpened the focus of our pipeline strategy , which now includes development of KIO - 301 , a treatment for a rare disease with a potentially expedited and cost - efficient path to market , " said Brian M. Strem , Ph.D. , President and Chief Executive Officer of Kiora . " We anticipate multiple upcoming milestones , including advancing KIO - 301 into the clinic next year , reporting topline data from our exploratory dry eye study of KIO - 101 and finalizing the design of our registration study for KIO - 201 in early 2022. " Recently , Kiora has achieved several milestones , including the following : Pipeline Updates • Acquired Bayon Therapeutics , Inc. in October , which brought in a portfolio of small molecule photoswitches , including KIO - 301 , which is designed to restore vision in patients with inherited and age - related degenerative retinal diseases . • Completed enrollment in a Phase 1 / 2a proof - of - concept study in September to evaluate KIO - 101 for the treatment of ocular surface inflammation . Corporate Updates • Appointed Eric J. Daniels , M.D. as Chief Development Officer in October to drive the ongoing development of Kiora's portfolio of clinical - stage assets , expanding pipeline , and proprietary platform . • Raised gross proceeds of $ 10.75 million through a registered direct offering in August to strengthen the company's financial position . • Appointed Brian M. Strem , Ph.D. as CEO in July bringing to the Company strategic and scientific expertise in ophthalmology . Kiora's pipeline now consists of three assets in early to late - stage development for both common and rare eye diseases . The Company anticipates achieving several milestones for these programs , including the following , which will drive value in the organization : • KIO - 101 , previously known as PP - 001 , is a next - generation small molecule inhibitor of Dihydroorotate Dehydrogenase ( " DHODH " ) . It has demonstrated picomolar potency with a validated mechanism ( blocks T - cell proliferation and proinflammatory cytokine